Clinical Trial

Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\>6.8 mg/dl) is a requirement for the formation of uric acid crystals. MSU crystals can be deposited in all tissues mainly in and around the joints forming tophi. Early presentation of gout is an acute joint inflammation that is quickly relieved by non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. Lowering SUA levels below deposition threshold either by dietary modification or using serum uric acid lowering drugs is the main goal in management of gout. This results in dissolution of MSU crystals preventing further attacks
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-20.
Status change: Not Yet Recruiting → Recruiting 2025-06-21
Trial Details
NCT Number NCT06995339
Lead Sponsor Mostafa Bahaa
Collaborators: Dalia Naser Abdel-Sadek Safa , Faculty of Pharmacy, Tanta University, Sahar Mohamed Elhaggar, Faculty of Pharmacy, Tanta University, Al-Azhar University
Conditions Gout
Enrollment 60 participants
Start Date 2025-05-30
Primary Completion 2026-08-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2025-06-24